Cyclohexanecarboxamide, N-[2-[(ethylsulfonyl)amino]-5-(trifluoromethyl)-3-pyridinyl]-, sodium salt, hydrate (1:1:1)

Fuzapladib sodium hydrate, also known as N-[2-(Sodioethanesulfonamido)-5-(trifluoromethyl)pyridin-3-yl]cyclohexanecarboxamide monohydrate, is a phospholipase A2 ( PLA2) inhibitor and a leukocyte function-associated antigen-1 (LFA-1) activation inhibitor for the treatment of acute pancreatitis (AP) in animal species (dogs).

Fuzapladib Sodium Hydrate is a synthetic anti-inflammatory agent that shows inhibitory effect on cytosolic phospholipase A2 (cPLA2).

Fuzapladib sodium hydrate controls the progression of pancreatitis by blocking the activation of adhesion molecules (integrins) expressed on the surface of inflammatory cells and preventing inflammatory cells from adhering to vascular endothelial cells and infiltrating tissues.